Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00978367

Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)

A Double Blind, Placebo (Vehicle) and Standard Care Controlled, Randomised Study to Investigate the Clinical Safety and Toleration (Including Systemic Pharmacokinetics), Wound Healing and Anti-scarring Potential of Two Applications of Intradermal RN1001 in Healthy Male Subjects.

Sponsor: Renovo

Conditions Cicatrix Re-epithelialization Wound Healing

Interventions Avotermin Placebo

Updated 4 times since 2017 Last updated: Sep 15, 2009 Started: Feb 28, 2002 Primary completion: Nov 30, 2002 Completion: Nov 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Cicatrix and Re-epithelialization, this trial is completed. The trial is conducted by Renovo and has accumulated 4 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Renovo

Data source: Renovo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Manchester, United Kingdom